logo
Share SHARE
FONT-SIZE Plus   Neg

Green Mountain Coffee Q2 Profit Meets Estimates; Cuts FY12 Outlook

Green Mountain Coffee Roasters, Inc. (GMCR) reported second-quarter net income attributable to the company of $93.0 million or $0.58 per share, up from $65.4 million or $0.44 per share last year.

Excluding items, non-GAAP net income for the quarter was $101.7 million or $0.64 per share, compared to $71.5 million or $0.48 per share.

On average, 11 analysts polled by Thomson Reuters expected earnings of $0.64 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter increased 37 percent to $885.1 million from $647.7 million a year ago.

Analysts expected revenues of $971.65 million for the quarter.

Looking forward, Green Mountain Coffee Roasters expects third-quarter non-GAAP earnings of $0.48 to $0.53 per share on net sales ranging from $861 million to $897 million. Analysts expect the company to earn $0.72 per share on revenue of $1.05 billion for the third quarter.

For the fiscal 2012 , the company expects non-GAAP earnings of $2.40 to $2.50 per share and net sales of $3.8 billion to $4.0 billion, which represents a net growth of 45% to 50%. Previously, the company expected non-GAAP earnings of $2.55 to $2.65 per share and net sales growth of 60% to 65%.

Analysts expect the company to earn $2.67 per share on revenues of $4.27 billion for the fiscal 2012.

Additionally, Green Mountain Coffee Roasters said that it has reached a multiyear agreement with Eight O'Clock Coffee Company to make Eight O'Clock coffee, Tetley tea, and Good Earth tea available in K-Cup and Vue packs for Keurig Single Cup Brewing systems. Financial terms of the agreement were not disclosed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Goldman Sachs downgraded the rating of retailer Target Corp. Thursday to sell from neutral over concerns about its increasing competition with e-commerce giant Amazon.com Inc. Target's price target was reduced to $67 from $77. It is expected that the retailer's efforts to compete with Amazon will result in sluggish sales and profits. Catabasis' phase II trial of Edasalonexent in boys affected by Duchenne muscular dystrophy is ongoing, and top-line results are anticipated in the first half of Q1 2017. American Express Co. (AXP) Thursday reported a drop in fourth-quarter profit, as revenues declined 4 percent due to absence of Costco portfolio while provisions for bad loans and marketing costs increased. Earnings fell short of Wall Street estimates, while revenues trumped expectations. New York-based...
comments powered by Disqus
Follow RTT